AcuTarget HD guides patient selection for Kamra inlay

Issue: May 25, 2015

SAN DIEGO — Choosing which patients are candidates to receive the newly FDA-approved AcuFocus Kamra inlay is enhanced when the company’s diagnostic AcuTarget HD device is used, according to a speaker at a company media event.

Perspective from David R. Hardten, MD

“[The AcuTarget HD] does preop and postop testing, and helps us decide who is a good candidate for the corneal inlay,” George O. Waring IV, MD, FACS, said.

The AcuTarget HD evaluates quality of vision, quantifies light scatter through the eye, assesses tear film quality, evaluates depth of focus loss and restoration, and guides inlay placement, according to the presentation.

Furthermore, the device can be applied to the diagnosis of astigmatism, hyperopia or myopia and to the surgical planning for laser vision correction, dysfunctional lens syndrome and dry eye, Waring said.

“This is no longer just about the inlay,” Waring said. “This helps us select treatment for a broad spectrum of patients, improves the patient experience, and most importantly, optimizes the outcomes.” - by Kristie L. Kahl

Disclosure: Waring is a consultant for and has received travel reimbursement from AcuFocus.

Perspective

David R. Hardten, MD

This presentation discusses important points regarding quality of vision. The AcuTarget HD instrument now provides an easy way to measure depth of focus, visual quality and tear film. This can be used to detect optical abnormalities that before were difficult to detect, especially with regard to lenticular irregularity from dysfunctional lens or early cataract. The ability to quantify visual blur from tear film abnormalities is also very useful. The clinical implications are broad, with the ability to measure patients whom you are following annually, as well as obtaining preoperative and postoperative measurements.

David R. Hardten, MD

OSN Cornea/External Disease Section Editor

Disclosures: Hardten reports no relevant financial disclosures.